Hansson, Oskar

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease

Schöll, M., Ossenkoppele, R., Strandberg, O., Palmqvist, S., study, T. S. B., Jögi, J., Ohlsson, T., Smith, R., & Hansson, O. (2017) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 180

Cerebrospinal fluid neurogranin and YKL ‐40 as biomarkers of Alzheimer's disease

Janelidze, S., Hertze, J., Zetterberg, H., Landqvist Waldö, M., Santillo, A., Blennow, K., & Hansson, O. (2016) · Annals of Clinical and Translational Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 179

18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., et al. (2017) · EMBO Molecular Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 177

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios

Janelidze, S., Barthélemy, N. R., He, Y., Bateman, R. J., & Hansson, O. (2023) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 176

18 F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., & Hansson, O. (2016) · Brain

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 168

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease

Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 168

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls

Martínez-Morillo, E., Hansson, O., Atagi, Y., Bu, G., Minthon, L., Diamandis, E. P., & Nielsen, H. M. (2014) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 168

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease

Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 168

Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease

Ossenkoppele, R., Lyoo, C. H., Jester-Broms, J., Sudre, C. H., Cho, H., Ryu, Y. H., Choi, J. Y., Smith, R., Strandberg, O., Palmqvist, S., et al. (2020) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 161

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease

Barthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2023) · Nature Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 153

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review

Brand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., et al. (2022) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 151

Increased CSF biomarkers of angiogenesis in Parkinson disease

Janelidze, S., Lindqvist, D., Francardo, V., Hall, S., Zetterberg, H., Blennow, K., Adler, C. H., Beach, T. G., Serrano, G. E., van Westen, D., et al. (2015) · Neurology

Parkinson's Disease Mechanisms and TreatmentsNeurological Disease Mechanisms and Treatments

Cited by 150

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 149

Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies

Mattsson-Carlgren, N., Collij, L. E., Stomrud, E., Pichet Binette, A., Ossenkoppele, R., Smith, R., Karlsson, L., Lantero-Rodriguez, J., Snellman, A., Strandberg, O., et al. (2024) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 148

Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment.

Janelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O. (2017) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 147

New landscape of the diagnosis of Alzheimer’s disease

Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 143

Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology

Grothe, M. J., Sepulcre, J., Gonzalez-Escamilla, G., Jelistratova, I., Schöll, M., Hansson, O., Teipel, S. J., & Initiative, A. D. N. (2018) · Brain

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 142

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 142

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 141

Tau PET Imaging in Neurodegenerative Disorders

Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 137

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 136

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 136

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease

Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 135

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability

Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., et al. (2024) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 131